Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
36
HQL Quote, Financials, Valuation and Earnings
Last price:
$13.47
Seasonality move
:
4.03%
Day range:
$13.16 - $13.54
52-week range:
$12.76 - $15.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
94.5K
Avg. volume:
99.2K
1-year change:
4.01%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus Ratingabrdn Life Sciences Investors has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, abrdn Life Sciences Investors has an estimated downside of -- from its current price of $13.50.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $13.50.
Fair Value
-
According to the consensus of 0 analysts, abrdn Life Sciences Investors has -- downside to fair value with a price target of -- per share.
HQL vs. S&P 500
-
Over the past 5 trading days, abrdn Life Sciences Investors has underperformed the S&P 500 by -0.48% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
abrdn Life Sciences Investors does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
abrdn Life Sciences Investors has grown year-over-year revenues for 0 quarters straight. In the most recent quarter abrdn Life Sciences Investors reported revenues of --.
Earnings Growth
-
abrdn Life Sciences Investors has grown year-over-year earnings for 0 quarters straight. In the most recent quarter abrdn Life Sciences Investors reported earnings per share of --.
Enterprise value:
--
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-24 | 2023-12-24 | 2023-12-24 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2017-03-31 | 2018-03-31 | 2019-03-31 | 2020-03-31 | 2021-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $130.5K | $6.1M | $4.5M | $49.4K | |
| Total Assets | -- | $437.6M | $427M | $402.1M | $503.3M | |
| Current Liabilities | -- | -- | $1.2M | -- | $44.1K | |
| Total Liabilities | -- | $687.2K | $1.8M | $585.2K | $649.6K | |
| Total Equity | -- | $436.9M | $425.1M | $401.5M | $502.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-24 | 2023-12-24 | 2023-12-24 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
HQL
Sector
Market Cap
--
--
Price % of 52-Week High
84.91%
--
Dividend Yield
0%
--
Shareholder Yield
--
--
1-Year Price Total Return
4.01%
--
Beta (5-Year)
0.748
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$13.71
200-day SMA
Sell
Level
$14.33
Bollinger Bands (100)
Sell
Level
14.26 - 15.38
Chaikin Money Flow
Buy
Level
13.1M
20-day SMA
Sell
Level
$13.98
Relative Strength Index (RSI14)
Sell
Level
37.01
ADX Line
Sell
Level
13.14
Williams %R
Neutral
Level
-71.294
50-day SMA
Sell
Level
$14.47
MACD (12, 26)
Sell
Level
-0.27
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
20.5M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
Stock Forecast FAQ
In the current month, HQL has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HQL average analyst price target in the past 3 months is --.
-
Where Will abrdn Life Sciences Investors Stock Be In 1 Year?
According to analysts, the consensus estimate is that abrdn Life Sciences Investors share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About abrdn Life Sciences Investors?
Analysts are divided on their view about abrdn Life Sciences Investors share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that abrdn Life Sciences Investors is a Sell and believe this share price will rise from its current level to --.
-
What Is abrdn Life Sciences Investors's Price Target?
The price target for abrdn Life Sciences Investors over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HQL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for abrdn Life Sciences Investors is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HQL?
You can purchase shares of abrdn Life Sciences Investors via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase abrdn Life Sciences Investors shares.
-
What Is The abrdn Life Sciences Investors Share Price Today?
abrdn Life Sciences Investors was last trading at $13.47 per share. This represents the most recent stock quote for abrdn Life Sciences Investors. Yesterday, abrdn Life Sciences Investors closed at $13.50 per share.
-
How To Buy abrdn Life Sciences Investors Stock Online?
In order to purchase abrdn Life Sciences Investors stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
